Analysis 1.1. Comparison 1 Any antibiotic versus control (individuals), Outcome 1 Active trachoma at 3 months. . Analysis 1.2. Comparison 1 Any antibiotic versus control (individuals), Outcome 2 Active trachoma at 12 months. . Analysis 1.3. Comparison 1 Any antibiotic versus control (individuals), Outcome 3 Active trachoma at 3 months (subgroup
A dose range study in 18 patients suffering from intestinal amoebiasis and treated with doses of panidazole between 1.0 and 2.0 g per day for six days revealed that the best therapeutic results were obtained with the higher dose. This dose was then compared with metronidazole, at the same dose, in a clinical trial in 100 patients with intestinal amoebiasis. Cure rates were 68% and 80% for the two drugs respectively. In 100 cases of vaginal trichomoniasis treated with panidazole at the dose of 1.0 g per day for seven days in half of the patients and for 10 days in the other half, we obtained 50% and 60% cure rates. The results of our studies with both amoebiasis and trichomoniasis were not superior to those obtained with metronidazole and other nitroimidazole derivatives. Side effects were found in 74% of the patients treated for amoebiasis and in 46% of the cases treated for trichomoniasis. No toxic effects were revealed by haematological, biochemical and renal function tests nor by cardiovascular studies.
adverse reactions (AR) such as aseptic meningitis (AM) are described in the product information (PI). Purpose To describe and analyse five cases of AM in patients treated with IVIg in our centre. Material and methods A literature search was conducted on the AR of IVIg. The case analysis was established using the Karch-Lasagna algorithm. Results There were five cases notified of AM in a 3 month period (80% females). Clinical manifestations included headache, fever, nausea and vomiting, and in some cases photophobia. Symptoms usually commenced within 48 hours after infusion. In all cases lumbar puncture was compatible with AM. Two patients had to be hospitalised due to AM, one of them prolonged hospitalisation.All patients received IVIg of the same brand, presentation and even some of the same batch. All of them received an individualised administration form prepared by the pharmacist including premedication information and the rate of administration of the IVIg calculated according to patient weight and PI.The Karch-Lasagna algorithm in these cases established a possible causal relationship between IVIg and the occurrence of AM.Every case reported had a neurological-based pathology: myasthaenia gravis, nystagmus, multiple mononeuropathy, Parsonage-Turner syndrome and sensitive-motor polyneuropathy. Nevertheless, in our centre the other five patients with no neurological pathology received the same presentation and batch of IVIg during the same period and did not present AM. The analysis leads us to suspect that patients with basic neurological diagnosis have a higher risk of suffering from AM.The preventive measures adopted were to reduce the speed of individualised administration and to insist that good hydration is important in preventing this adverse effect. Conclusion IVIg have demonstrated efficacy and a good safety profile in clinical trials. However, possible AR due to its use can be observed. The role of the pharmacist is important in the individualised information by patients concerning the administration of immunoglobulins. In order to reduce the incidence of AM, it is suggested to start the initial infusion at a slow rate, prehydration and premedication therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.